Federal Research Institute Of Pediatric Hematology, Oncology And Immunology
Clinical trials sponsored by Federal Research Institute Of Pediatric Hematology, Oncology And Immunology, explained in plain language.
-
New hope for kids with aggressive nerve cancer: immune-boosting combo trial opens
Disease control Recruiting nowThis phase 3 trial tests a powerful mix of chemotherapy, immunotherapy, and the child's own natural killer (NK) cells for children aged 1.5 to 18 with high-risk neuroblastoma that didn't respond or came back. The goal is to shrink tumors and improve survival by helping the immune…
Phase: PHASE3 • Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New cell cocktail aims to prevent transplant complications in kids with leukemia
Disease control Recruiting nowThis study tests a new method to prevent graft-versus-host disease (GVHD) in children and young adults with high-risk blood cancers who need a stem cell transplant from a half-matched donor. The approach combines specially enriched donor immune cells with a stem cell graft that h…
Phase: PHASE2, PHASE3 • Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Immune booster: donor NK cells aim to stop leukemia return after transplant
Disease control Recruiting nowThis clinical trial tests whether infusions of donor natural killer (NK) cells, given before and after a stem cell transplant, can safely prevent leukemia from coming back in children and young adults with hard-to-treat acute leukemia. The study enrolls 15 patients aged 0 to 25 w…
Phase: PHASE2 • Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New chemo regimen aims to boost survival in kids with down syndrome and leukemia
Disease control Recruiting nowThis study is testing a specific set of four chemotherapy blocks in children (0-18 years) who have both acute myeloid leukemia (AML) and Down syndrome. The goal is to see if this tailored treatment can improve long-term survival and reduce harsh side effects compared to past appr…
Phase: PHASE3 • Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC